13 research outputs found
Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts
At an online meeting of experts held on May 14, 2021 additional research results on a sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with reduced ejection fraction were considered. According to the data from the EMPEROR-Reduced international study, cardiovascular and renal effects of empagliflozin therapy in patients with and without type 2 diabetes (T2D) were analyzed. A number of proposals and recommendations was accepted regarding the further study of cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with heart failure, regardless of the T2D presence
Hypoglycemia and hyperglycemia: potential risks of polypragmasia in type 2 diabetes in hospital settings
Chronic hyperglycemia imposes damage on a number of cell types and is strongly correlated with the variety of related complications such as eyes, kidneys, cardiovascular system etc. This fact implies pharmacological treatment. Some are metabolic neutral, some are apt to provoke hypoglycemia and/or hyperglycemia, invert pharmacological response. To take into account a potential role of treatment on glucose level is crucial for pharmacotherapy in patient with T2DM. Besides, some drugs may distort the meaning of lab tests